Required to reconstitute lyophilized peptides before use in research.
MOLECULAR WEIGHT
Daltons
AMINO ACIDS
Peptide sequence
STUDIES
Published research
PURITY
HPLC verified
Key findings from published peer-reviewed research studies.
Avg Weight Reduction
HbA1c Reduction
SURMOUNT-1 Duration
GIP/GLP-1 Agonist
Superior HbA1c reduction compared to existing treatments
Phase 3 SURPASS trial data demonstrated dose-dependent HbA1c reductions of up to 2.58% from baseline, surpassing the efficacy of comparator agents.
Significant weight loss of up to 22.5% of body weight in clinical trials
SURMOUNT-1 trial showed participants receiving the highest dose achieved an average weight reduction of 22.5% over 72 weeks, representing a landmark finding in metabolic research.
Significant weight loss of up to 22.5% of body weight in clinical trials
SURMOUNT-1 trial showed participants receiving the highest dose achieved an average weight reduction of 22.5% over 72 weeks, representing a landmark finding in metabolic research.
Improvements in cardiovascular risk factors including lipid profiles
Data showed reductions in total cholesterol, triglycerides, and LDL-C, alongside improvements in blood pressure and inflammatory biomarkers.
First-in-class dual GIP/GLP-1 receptor agonism provides enhanced efficacy
The dual incretin mechanism amplifies insulin secretion, suppresses glucagon, slows gastric emptying, and influences central appetite regulation pathways.
Hypoglycemia Risk
GI Side Effects
Pancreatic Profile
Most commonly reported: nausea, diarrhea, and decreased appetite. These effects were generally mild-to-moderate and transient, diminishing with continued use.
No increased risk of pancreatitis observed across clinical trial programs. Lipase/amylase elevations were monitored and remained within acceptable ranges.
GLP-1 receptor agonists carry a class warning regarding thyroid C-cell tumors observed in rodent studies. Clinical relevance in humans remains under investigation.
Low risk of hypoglycemia when used alone. Risk increases when combined with insulin or sulfonylureas in research protocols.
Mild injection site reactions (redness, itching) reported in a small percentage of study participants, typically resolving without intervention.
Disclaimer: This product is intended for research use only. Not for human consumption, therapeutic use, or diagnostic purposes.
4,813 Da
39
≥99%
<0.1 EU/mg
| Chemical Name | Tirzepatide |
| CAS Number | 2023788-19-2 |
| Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ |
| Molecular Weight | 4,813.45 g/mol |
| Peptide Length | 39 amino acids |
| Mechanism | Dual GIP/GLP-1 receptor agonist |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in sterile water, bacteriostatic water |
| Purity | ≥99% (HPLC) |
| Endotoxin Level | <0.1 EU/mg |
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It was developed for metabolic research and has shown unprecedented efficacy in clinical trials.
Unlike GLP-1-only agonists (e.g., semaglutide), tirzepatide activates both GIP and GLP-1 receptors. This dual mechanism provides additive effects on insulin secretion, glucose control, and weight management in research models.
SURPASS is a series of Phase 3 clinical trials evaluating tirzepatide for type 2 diabetes. SURMOUNT trials investigate its use in obesity research. Both programs have demonstrated best-in-class efficacy.
Store lyophilized tirzepatide at -20°C for long-term storage. Reconstituted solution should be stored at 2-8°C and used within 14 days.
Each batch undergoes HPLC purity analysis, mass spectrometry for identity, endotoxin testing, sterility testing, and residual solvent analysis to ensure pharmaceutical-grade quality.
Peer-reviewed publications and reference materials.
Our products are strictly intended for laboratory research use only. Not for human or animal consumption. By purchasing, you confirm that you are a licensed researcher or purchasing for research purposes.